Dose-ranging efficacy study of topical NEOSH101 to treat male pattern hair loss

Journal of Drugs in Dermatology, Oct, 2007

Sponsored by Neosil, Inc. The purpose of this study is to evaluate the safety and efficacy of 3 doses of topical NEOSH101 applied once-daily for 16 weeks in men with thinning hair in the top and center of the scalp (Norwood/Hamilton grades III-IV androgenetic alopecia).

Condition     Intervention                            Phase

Androgenetic  Drug: tetrapeptide aldehyde proteasome  Phase II
  Alopecia      inhibitor (NEOSH101)

Study ID Numbers: NEOSH101-CLIN-AGA004

ClinicalTrials.gov Identifier: NCT00471510